BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 23079962)

  • 1. Towards effective and safe immunotherapy after allogeneic stem cell transplantation: identification of hematopoietic-specific minor histocompatibility antigen UTA2-1.
    Oostvogels R; Minnema MC; van Elk M; Spaapen RM; te Raa GD; Giovannone B; Buijs A; van Baarle D; Kater AP; Griffioen M; Spierings E; Lokhorst HM; Mutis T
    Leukemia; 2013 Mar; 27(3):642-9. PubMed ID: 23079962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens.
    Warren EH; Fujii N; Akatsuka Y; Chaney CN; Mito JK; Loeb KR; Gooley TA; Brown ML; Koo KK; Rosinski KV; Ogawa S; Matsubara A; Appelbaum FR; Riddell SR
    Blood; 2010 May; 115(19):3869-78. PubMed ID: 20071660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of 4 new HLA-DR-restricted minor histocompatibility antigens as hematopoietic targets in antitumor immunity.
    Stumpf AN; van der Meijden ED; van Bergen CA; Willemze R; Falkenburg JH; Griffioen M
    Blood; 2009 Oct; 114(17):3684-92. PubMed ID: 19706888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minor histocompatibility antigens as targets for immunotherapy using allogeneic immune reactions.
    Akatsuka Y; Morishima Y; Kuzushima K; Kodera Y; Takahashi T
    Cancer Sci; 2007 Aug; 98(8):1139-46. PubMed ID: 17521316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Up-regulated expression in nonhematopoietic tissues of the BCL2A1-derived minor histocompatibility antigens in response to inflammatory cytokines: relevance for allogeneic immunotherapy of leukemia.
    Kloosterboer FM; van Luxemburg-Heijs SA; van Soest RA; van Egmond HM; Willemze R; Falkenburg JH
    Blood; 2005 Dec; 106(12):3955-7. PubMed ID: 16099884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimized Whole Genome Association Scanning for Discovery of HLA Class I-Restricted Minor Histocompatibility Antigens.
    Fuchs KJ; Honders MW; van der Meijden ED; Adriaans AE; van der Lee DI; Pont MJ; Monajemi R; Kielbasa SM; 't Hoen PAC; van Bergen CAM; Falkenburg JHF; Griffioen M
    Front Immunol; 2020; 11():659. PubMed ID: 32362897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of 4 novel HLA-B*40:01 restricted minor histocompatibility antigens and their potential as targets for graft-versus-leukemia reactivity.
    Griffioen M; Honders MW; van der Meijden ED; van Luxemburg-Heijs SA; Lurvink EG; Kester MG; van Bergen CA; Falkenburg JH
    Haematologica; 2012 Aug; 97(8):1196-204. PubMed ID: 22419570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens.
    Dickinson AM; Wang XN; Sviland L; Vyth-Dreese FA; Jackson GH; Schumacher TN; Haanen JB; Mutis T; Goulmy E
    Nat Med; 2002 Apr; 8(4):410-4. PubMed ID: 11927949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HA-1H T-Cell Receptor Gene Transfer to Redirect Virus-Specific T Cells for Treatment of Hematological Malignancies After Allogeneic Stem Cell Transplantation: A Phase 1 Clinical Study.
    van Balen P; Jedema I; van Loenen MM; de Boer R; van Egmond HM; Hagedoorn RS; Hoogstaten C; Veld SAJ; Hageman L; van Liempt PAG; Zwaginga JJ; Meij P; Veelken H; Falkenburg JHF; Heemskerk MHM
    Front Immunol; 2020; 11():1804. PubMed ID: 32973756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Minor antigens - major impact. The role of minor histocompatibility antigens in allogeneic hematopoietic stem cell transplantation].
    Hudecek M; Bartsch K; Tschiedel S; Niederwieser D
    Dtsch Med Wochenschr; 2008 Jul; 133(28-29):1511-6. PubMed ID: 18597211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Possible role of minor h antigens in the persistence of donor chimerism after stem cell transplantation; relevance for sustained leukemia remission.
    van der Torren CR; van Hensbergen Y; Luther S; Aghai Z; Rychnavská ZS; Slot M; Scherjon S; Kröger N; Ganser A; Weissinger EM; Goulmy E; Hambach L
    PLoS One; 2015; 10(3):e0119595. PubMed ID: 25774796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The DBY gene codes for an HLA-DQ5-restricted human male-specific minor histocompatibility antigen involved in graft-versus-host disease.
    Vogt MH; van den Muijsenberg JW; Goulmy E; Spierings E; Kluck P; Kester MG; van Soest RA; Drijfhout JW; Willemze R; Falkenburg JH
    Blood; 2002 Apr; 99(8):3027-32. PubMed ID: 11929796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting haematopoietic-specific minor histocompatibility antigens to distinguish graft-versus-tumour effects from graft-versus-host disease.
    Spaapen R; Mutis T
    Best Pract Res Clin Haematol; 2008 Sep; 21(3):543-57. PubMed ID: 18790454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease.
    Mutis T; Gillespie G; Schrama E; Falkenburg JH; Moss P; Goulmy E
    Nat Med; 1999 Jul; 5(7):839-42. PubMed ID: 10395333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rebuilding human leukocyte antigen class II-restricted minor histocompatibility antigen specificity in recall antigen-specific T cells by adoptive T cell receptor transfer: implications for adoptive immunotherapy.
    Spaapen R; van den Oudenalder K; Ivanov R; Bloem A; Lokhorst H; Mutis T
    Clin Cancer Res; 2007 Jul; 13(13):4009-15. PubMed ID: 17606735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia.
    de Rijke B; van Horssen-Zoetbrood A; Beekman JM; Otterud B; Maas F; Woestenenk R; Kester M; Leppert M; Schattenberg AV; de Witte T; van de Wiel-van Kemenade E; Dolstra H
    J Clin Invest; 2005 Dec; 115(12):3506-16. PubMed ID: 16322791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting minor histocompatibility antigens in graft versus tumor or graft versus leukemia responses.
    Feng X; Hui KM; Younes HM; Brickner AG
    Trends Immunol; 2008 Dec; 29(12):624-32. PubMed ID: 18952501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple myeloma-reactive T cells recognize an activation-induced minor histocompatibility antigen encoded by the ATP-dependent interferon-responsive (ADIR) gene.
    van Bergen CA; Kester MG; Jedema I; Heemskerk MH; van Luxemburg-Heijs SA; Kloosterboer FM; Marijt WA; de Ru AH; Schaafsma MR; Willemze R; van Veelen PA; Falkenburg JH
    Blood; 2007 May; 109(9):4089-96. PubMed ID: 17234742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expanding the immunotherapeutic potential of minor histocompatibility antigens.
    Spierings E; Goulmy E
    J Clin Invest; 2005 Dec; 115(12):3397-400. PubMed ID: 16322786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens.
    Tykodi SS; Warren EH; Thompson JA; Riddell SR; Childs RW; Otterud BE; Leppert MF; Storb R; Sandmaier BM
    Clin Cancer Res; 2004 Dec; 10(23):7799-811. PubMed ID: 15585611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.